

Supplementary Data

Supplementary Figure 1: Minimal toxicity of systemic nanovector in mice

A series of hematological and biochemical assays were performed in cohorts of mice receiving miR-143/45 nanovector *versus* delivery buffer (5% glucose) via tail vein injection. Each mouse was treated thrice weekly for two weeks. No significant differences were observed in hemoglobin (Hb), red blood cell count (RBC), white blood cell count (WBC), or platelet count (PLT). Additionally, liver function tests (ALT and AST) and renal function tests (Creatinine and BUN) did not demonstrate any significant differences from buffer control.